Healios K.K. researches and develops iPSC Regenerative Medicine and Compound Drugs. The company researches for the development of treatment for Age-Related Macular Degeneration.

(Delayed) Appointment Of D.J. Skelton As An Advisor To Healios

Status Of Conditional And Time-Limited Approval Application For Ards In Japan

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

HEALIOS KK (4593 JP)

(Delayed) Appointment Of D.J. Skelton As An Advisor To Healios

Status Of Conditional And Time-Limited Approval Application For Ards In Japan

Announcement Of Changes In Management

Healios Selected For The Amed “Project To Promote The Industrialization Of Regenerative/Cell Medicine And Gene Therapy”

Fy2024 Q3 Financial Results

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)